GLP-1 Weight Loss in Houston: What to Know Before You Start
Medical oversight: Micah Craig, MD, Medical Director, Valere Regenerative
Few medications have changed a field as quickly as the GLP-1 class. Semaglutide and tirzepatide are now household names in Houston, and many people can get a prescription through a short telehealth visit. That access is useful. It also leaves out most of what decides how a person feels a year later: which medication fits, how the dose is built, what happens to muscle, and what the plan is if the medication stops.
This article explains what GLP-1 medications are, what the major trials actually reported, the side effects and safety questions worth knowing, and how a physician-led program in River Oaks approaches medical weight loss. It is written for adults weighing their options, not as a recommendation for any one person.
What GLP-1 medications are and how they work
GLP-1 (glucagon-like peptide-1) is an incretin hormone the gut releases after eating. Medications that act on the GLP-1 receptor slow gastric emptying, signal fullness to the brain and help regulate blood sugar. The practical effect for most people is a quieter appetite and smaller portions without constant effort.
Two names dominate the conversation:
Semaglutide is a GLP-1 receptor agonist. As Wegovy, it is FDA-approved for chronic weight management in adults with obesity, or with overweight and at least one weight-related condition. Ozempic is the same molecule approved for type 2 diabetes.
Tirzepatide acts on two receptors, GIP and GLP-1. As Zepbound, the FDA approved it for chronic weight management in November 2023. Mounjaro is the same molecule approved for type 2 diabetes.
Both are once-weekly injections, started at a low dose and increased gradually over several months to limit side effects.
What the major trials reported
The headline numbers come from large, placebo-controlled trials published in the New England Journal of Medicine. They are worth reading carefully, because averages describe groups, not individuals.
Semaglutide 2.4 mg (STEP 1). In 1,961 adults without diabetes, average weight change over 68 weeks was −14.9% with semaglutide versus −2.4% with placebo, alongside a lifestyle intervention (Wilding et al., 2021).
Tirzepatide (SURMOUNT-1). In 2,539 adults without diabetes, average weight change at 72 weeks ranged from −15.0% on 5 mg to −20.9% on 15 mg, versus −3.1% with placebo (Jastreboff et al., 2022).
Heart outcomes (SELECT). In 17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes, semaglutide was associated with a 20% lower relative risk of cardiovascular death, heart attack or stroke compared with placebo (Lincoff et al., 2023). The FDA added this cardiovascular indication to Wegovy in 2024.
Two caveats matter. First, every one of these trials paired medication with diet and activity counselling, so the results reflect medication plus a structured plan. Second, the spread around the average was wide: some participants lost far more, and some lost little. Results vary, and no one can promise a specific number.
What happens when the medication stops
One of the most useful studies for anyone considering a GLP-1 is the one people hear about least. In the STEP 1 extension, participants who stopped semaglutide and the lifestyle program regained roughly two-thirds of the weight they had lost within a year, and most cardiometabolic improvements drifted back toward baseline (Wilding et al., 2022).
The authors' conclusion is that obesity behaves like a chronic condition. In practice, that means the question is not only "how do I lose weight?" but "what is my plan for the long term?" That plan may involve continuing medication, adjusting the dose, or building the habits and body composition that make maintenance more realistic. It is a decision to make with a physician, ideally before starting.
The muscle question
The scale reports total weight. It does not report what that weight was made of. Any significant weight loss includes some lean tissue, and studies of GLP-1 medications have reported a wide range in how much of the loss came from lean mass.
For adults in their forties, fifties and beyond, that matters. Muscle supports strength, balance, glucose handling and independence later in life. A program designed around body composition measures it at baseline, tracks it through treatment and builds in the inputs known to protect it: adequate protein, progressive resistance training and attention to the hormonal environment.
Side effects and safety
The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation and abdominal discomfort, usually most noticeable during dose increases. Slower titration often helps.
FDA labeling for these medications also includes important warnings. They carry a boxed warning about thyroid C-cell tumors seen in rodent studies, and they should not be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Labeling also describes risks including pancreatitis, gallbladder problems, low blood sugar when combined with certain diabetes medications, kidney injury from dehydration, and others (FDA). This is part of why a full history and baseline labs come before a prescription, not after.
A note on compounded and unapproved GLP-1 products
The FDA has stated that compounded and other unapproved versions of these medications do not go through its review for safety, effectiveness and quality before they are marketed. It has also reported dosing errors and adverse events linked to compounded semaglutide and tirzepatide, and has warned about counterfeit products and items sold "for research purposes" (FDA). Whatever you are prescribed, it is reasonable to ask exactly what the medication is, where it comes from and how it should be stored and dosed.
Who may be a candidate
FDA-approved GLP-1 weight-management medications are indicated for adults with a body-mass index of 30 or higher, or 27 or higher with at least one weight-related condition such as high blood pressure, high cholesterol or type 2 diabetes, used alongside reduced-calorie eating and increased physical activity. Eligibility for any individual is a physician decision based on history, examination and labs.
Many of the people we see in River Oaks fall into one of two groups. Some have already tried a GLP-1 through a telehealth service and want more structure, especially around muscle and long-term maintenance. Others noticed their body composition change in their forties or through perimenopause without any change in what they were doing, and want to understand why.
How a physician-led program in Houston approaches it
At Valere Regenerative, the medication is one tool inside a program, not the program itself. Our medical weight loss and metabolic health program is built in three steps:
Assessment and panel. A 45-minute physician-led conversation and a panel that reads insulin and glucose handling, thyroid, cortisol, sex hormones and safety markers, plus a baseline body composition measurement.
A plan built around the cause. If a GLP-1 is clinically appropriate, the physician chooses the medication, dose and pace of titration with you. Where the panel points to hormones as a driver, HRT or TRT may be addressed alongside. Where it supports it, a peptide protocol may be considered as part of the same plan.
Follow-up and adjustment. Repeat labs, composition tracking and dose adjustments over time, with a plan for maintenance agreed in advance rather than improvised later.
GLP-1 medications are prescribed only where clinically indicated following physician evaluation. Eligibility, dosing and duration are determined by the licensed physician, and individual results vary.
Frequently asked questions
Is semaglutide or tirzepatide better?
In SURMOUNT-1 and STEP 1, average weight loss was larger with tirzepatide, but the trials were separate and enrolled different people. The better choice depends on your history, tolerance, other conditions and goals, and is made with your physician.
I already have a GLP-1 prescription from telehealth. Can I still be seen?
Yes. Many patients come to us mid-treatment. We review what you are taking, your response so far and your labs, and build a program around body composition and maintenance.
Will I lose muscle on a GLP-1?
Some lean tissue loss accompanies most significant weight loss. How much varies. Measuring composition, eating enough protein and doing resistance training are the most practical ways to protect it, and they are built into each program.
How long will I need to take it?
There is no single answer. Trial data show weight regain is common after stopping, so duration and a maintenance plan are discussed at the start and revisited as you progress.
Do you accept insurance?
Valere does not accept insurance. Program details are reviewed with you after your assessment.
Reserve your assessment
If you are considering a GLP-1 in Houston, or you are already on one and want a more complete plan, the first step is a conversation. Reserve your assessment at our River Oaks institute, 919 W Gray St, and we will look at the full picture before recommending anything.
Medical disclaimer: This article is for general education only and is not medical advice. Reading it does not create a doctor–patient relationship. The treatments discussed are not right for everyone, individual results vary and are not guaranteed, and some therapies mentioned may be used off-label or are not FDA-approved for the uses described. Please talk with a licensed physician about your own health before starting any treatment.
